Download PDF
Semin Respir Crit Care Med 2013; 34(05): 600-619
DOI: 10.1055/s-0033-1356548
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary Hypertension Complicating Interstitial Lung Disease and COPD

Michael Y. Shino
1   Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Joseph P. Lynch III
1   Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Rajeev Saggar
2   Division of Pulmonary and Critical Care Medicine, Department of Medicine, Heart-Lung Institute, St. Joseph Hospital and Medical Center, Phoenix, Arizona
,
Fereidoun Abtin
3   Division of Thoracic Imaging and Intervention, Department of Radiological Sciences, UCLA Medical Center, Los Angeles, California
,
John A. Belperio
1   Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Rajan Saggar
1   Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2013 (online)

    Permissions and Reprints

Abstract

Pulmonary hypertension (PH) may complicate parenchymal lung disease, specifically interstitial lung diseases and chronic obstructive pulmonary disease, and uniformly increases the mortality risk. The epidemiology and degree of PH is variable and unique to the underlying lung disease. The clinician should exercise a high index of suspicion for PH complicating parenchymal lung disease especially given the nonspecific symptomatology and the limitations of echocardiography in this patient population. In general, PH-specific therapies in this setting have been poorly studied, with concern for increased shunting and/or ventilation/perfusion (V/Q) mismatch and resultant hypoxemia. A better understanding of the mechanisms underlying PH related to parenchymal lung disease may lead to novel pharmacological targets to prevent or treat this serious complication.

Keywords

interstitial lung disease - pulmonary hypertension - idiopathic pulmonary fibrosis - sarcoidosis - chronic obstructive pulmonary disease
 

  • References

  • 1 Nadrous HF, Pellikka PA, Krowka MJ , et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128 (4) 2393-2399
    CrossrefPubMedGoogle Scholar
  • 2 Fell CD, Martinez FJ. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 641-643
    CrossrefPubMedGoogle Scholar
  • 3 Nunes H, Humbert M, Capron F , et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (1) 68-74
    CrossrefPubMedGoogle Scholar
  • 4 Badesch DB, Tapson VF, McGoon MD , et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132 (6) 425-434
    PubMedGoogle Scholar
  • 5 Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167 (4) 580-586
    CrossrefPubMedGoogle Scholar
  • 6 Trad S, Amoura Z, Beigelman C , et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54 (1) 184-191
    CrossrefPubMedGoogle Scholar
  • 7 Launay D, Sitbon O, Le Pavec J , et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49 (3) 490-500
    CrossrefPubMedGoogle Scholar
  • 8 Fartoukh M, Humbert M, Capron F , et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161 (1) 216-223
    CrossrefPubMedGoogle Scholar
  • 9 Le Pavec J, Lorillon G, Jaïs X , et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142 (5) 1150-1157
    CrossrefPubMedGoogle Scholar
  • 10 Meraj R, Wikenheiser-Brokamp KA, Young LR, McCormack FX. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 2012; 33 (5) 486-497
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Cottin V, Harari S, Humbert M , et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40 (3) 630-640
    CrossrefPubMedGoogle Scholar
  • 12 Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129 (3) 746-752
    CrossrefPubMedGoogle Scholar
  • 13 Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122 (1) 233-238
    CrossrefPubMedGoogle Scholar
  • 14 Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11 (5) 452-455
    CrossrefPubMedGoogle Scholar
  • 15 Chaouat A, Bugnet AS, Kadaoui N , et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172 (2) 189-194
    CrossrefPubMedGoogle Scholar
  • 16 Saggar R, Saggar R, Aboulhosn J, Belperio JA, Zisman DA, Lynch III JP. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30 (4) 399-410
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Hoeper MM, Lee SH, Voswinckel R , et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48 (12) 2546-2552
    CrossrefPubMedGoogle Scholar
  • 18 Arcasoy SM, Christie JD, Ferrari VA , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (5) 735-740
    CrossrefPubMedGoogle Scholar
  • 19 Nathan SD, Shlobin OA, Barnett SD , et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102 (9) 1305-1310
    CrossrefPubMedGoogle Scholar
  • 20 Zisman DA, Ross DJ, Belperio JA , et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101 (10) 2153-2159
    CrossrefPubMedGoogle Scholar
  • 21 Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139 (5) 988-993
    CrossrefPubMedGoogle Scholar
  • 22 Adkins JM, Collard HR. Idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2012; 33 (5) 433-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Raghu G, Collard HR, Egan JJ , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (6) 788-824
    CrossrefPubMedGoogle Scholar
  • 24 Lynch III JP, Saggar R, Weigt SS, Zisman DA, White ES. Usual interstitial pneumonia. Semin Respir Crit Care Med 2006; 27 (6) 634-651
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174 (7) 810-816
    CrossrefPubMedGoogle Scholar
  • 26 Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61 (11) 980-985
    CrossrefPubMedGoogle Scholar
  • 27 Whelan TP, Dunitz JM, Kelly RF , et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24 (9) 1269-1274
    CrossrefPubMedGoogle Scholar
  • 28 Lynch III JP, Saggar R, Weigt SS, Ross DJ, Belperio JA. Overview of lung transplantation and criteria for selection of candidates. Semin Respir Crit Care Med 2006; 27 (5) 441-469
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Simonneau G, Galiè N, Rubin LJ , et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12, Suppl S ): 5S-12S
    CrossrefPubMedGoogle Scholar
  • 30 Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174 (6) 659-664
    CrossrefPubMedGoogle Scholar
  • 31 Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 657-663
    CrossrefPubMedGoogle Scholar
  • 32 Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132 (3) 998-1006
    CrossrefPubMedGoogle Scholar
  • 33 Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30 (4) 715-721
    CrossrefPubMedGoogle Scholar
  • 34 Nathan S, Saggar R . III JL. Lung transplantation for interstitial lung disorders. In: Lynch III JP, Ross DJ, , eds. Lung and Heart-Lung Transplantation. New York, NY: Taylor & Francis Group; 2006: 165-204
    Google Scholar
  • 35 Colombat M, Mal H, Groussard O , et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: Histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38 (1) 60-65
    CrossrefPubMedGoogle Scholar
  • 36 Cassan SM, Divertie MB, Brown Jr AL. Fine structural morphometry on biopsy specimens of human lung. 2. Diffuse idiopathic pulmonary fibrosis. Chest 1974; 65 (3) 275-278
    CrossrefPubMedGoogle Scholar
  • 37 Leach RM, Treacher DF. Clinical aspects of hypoxic pulmonary vasoconstriction. Exp Physiol 1995; 80 (5) 865-875
    PubMedGoogle Scholar
  • 38 Wood JG, Johnson JS, Mattioli LF, Gonzalez NC. Systemic hypoxia increases leukocyte emigration and vascular permeability in conscious rats. J Appl Physiol 2000; 89 (4) 1561-1568
    PubMedGoogle Scholar
  • 39 Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963; 18: 225-237
    CrossrefPubMedGoogle Scholar
  • 40 Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164 (12) 2239-2242
    CrossrefPubMedGoogle Scholar
  • 41 Keane MP, Arenberg DA, Lynch III JP , et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159 (3) 1437-1443
    PubMedGoogle Scholar
  • 42 Renzoni EA, Walsh DA, Salmon M , et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167 (3) 438-443
    CrossrefPubMedGoogle Scholar
  • 43 Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157 (1) 219-229
    CrossrefPubMedGoogle Scholar
  • 44 Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005; 108 (6) 479-491
    CrossrefPubMedGoogle Scholar
  • 45 Uguccioni M, Pulsatelli L, Grigolo B , et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995; 48 (4) 330-334
    CrossrefPubMedGoogle Scholar
  • 46 Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341 (8860) 1550-1554
    CrossrefPubMedGoogle Scholar
  • 47 Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165 (9) 1209-1216
    CrossrefPubMedGoogle Scholar
  • 48 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351 (14) 1425-1436
    CrossrefPubMedGoogle Scholar
  • 49 Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007; 28 (1) 117-125 , viii
    CrossrefPubMedGoogle Scholar
  • 50 Tuder RM, Cool CD, Geraci MW , et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159 (6) 1925-1932
    CrossrefPubMedGoogle Scholar
  • 51 Zisman DA, Karlamangla AS, Kawut SM , et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008; 133 (3) 640-645
    CrossrefPubMedGoogle Scholar
  • 52 Ghanem MK, Makhlouf HA, Agmy GR, Imam HM, Fouad DA. Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients. Ann Thorac Med 2009; 4 (4) 187-196
    CrossrefPubMedGoogle Scholar
  • 53 Modrykamien AM, Gudavalli R, McCarthy K, Parambil J. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care 2010; 55 (5) 584-588
    PubMedGoogle Scholar
  • 54 Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16 (3) 439-445
    CrossrefPubMedGoogle Scholar
  • 55 Boutou AK, Pitsiou GG, Trigonis I , et al. Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology 2011; 16 (3) 451-458
    CrossrefPubMedGoogle Scholar
  • 56 Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249 (3) 1042-1049
    CrossrefPubMedGoogle Scholar
  • 57 Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW. Medical College of Wisconsin Lung Transplant Group. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 1998; 113 (5) 1250-1256
    CrossrefPubMedGoogle Scholar
  • 58 Murray TI, Boxt LM, Katz J, Reagan K, Barst RJ. Estimation of pulmonary artery pressure in patients with primary pulmonary hypertension by quantitative analysis of magnetic resonance images. J Thorac Imaging 1994; 9 (3) 198-204
    CrossrefPubMedGoogle Scholar
  • 59 Nagaya N, Nishikimi T, Okano Y , et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31 (1) 202-208
    CrossrefPubMedGoogle Scholar
  • 60 Krüger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40 (4) 718-722
    CrossrefPubMedGoogle Scholar
  • 61 Leuchte HH, Neurohr C, Baumgartner R , et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170 (4) 360-365
    CrossrefPubMedGoogle Scholar
  • 62 Leuchte HH, Baumgartner RA, Nounou ME , et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173 (7) 744-750
    CrossrefPubMedGoogle Scholar
  • 63 Corte TJ, Wort SJ, Gatzoulis MA , et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36 (4) 819-825
    CrossrefPubMedGoogle Scholar
  • 64 Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009; 103 (2) 180-186
    CrossrefPubMedGoogle Scholar
  • 65 Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6.  min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011; 18 (5) 283-287
    PubMedGoogle Scholar
  • 66 Lederer DJ, Caplan-Shaw CE, O'Shea MK , et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006; 6 (2) 398-403
    CrossrefPubMedGoogle Scholar
  • 67 Lederer DJ, Arcasoy SM, Barr RG , et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant 2006; 6 (10) 2436-2442
    CrossrefPubMedGoogle Scholar
  • 68 Hamada K, Nagai S, Tanaka S , et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 650-656
    CrossrefPubMedGoogle Scholar
  • 69 Alam S, Palevsky HI. Standard therapies for pulmonary arterial hypertension. Clin Chest Med 2007; 28 (1) 91-115 , viii
    CrossrefPubMedGoogle Scholar
  • 70 O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007; 28 (1) 169-185 , ix
    CrossrefPubMedGoogle Scholar
  • 71 Galiè N, Torbicki A, Barst R , et al; Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25 (24) 2243-2278
    CrossrefPubMedGoogle Scholar
  • 72 Galiè N, Hoeper MM, Humbert M , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
    CrossrefPubMedGoogle Scholar
  • 73 Pitsiou G, Papakosta D, Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration 2011; 82 (3) 294-304
    CrossrefPubMedGoogle Scholar
  • 74 Olschewski H, Ghofrani HA, Walmrath D , et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2) 600-607
    CrossrefPubMedGoogle Scholar
  • 75 Ghofrani HA, Wiedemann R, Rose F , et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337) 895-900
    CrossrefPubMedGoogle Scholar
  • 76 Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 897-899
    CrossrefPubMedGoogle Scholar
  • 77 Han MK, Bach DS, Hagan P , et al. Sildenafil Preserves Exercise Capacity in IPF Patients with Right Ventricular Dysfunction. Chest 2013; ;(Jan): 24
    PubMedGoogle Scholar
  • 78 Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363 (7) 620-628
    CrossrefPubMedGoogle Scholar
  • 79 Corte TJ, Gatzoulis MA, Parfitt L, Harries C, Wells AU, Wort SJ. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 2010; 15 (8) 1226-1232
    CrossrefPubMedGoogle Scholar
  • 80 Raghu G, King Jr TE, Behr J , et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35 (1) 118-123
    CrossrefPubMedGoogle Scholar
  • 81 King Jr TE, Behr J, Brown KK , et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177 (1) 75-81
    CrossrefPubMedGoogle Scholar
  • 82 King Jr TE, Brown KK, Raghu G , et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184 (1) 92-99
    CrossrefPubMedGoogle Scholar
  • 83 Saggar R, Ross D, Lynch III J, Faul JL. Pulmonary arterial hypertension and lung transplantation. In: Lynch III JP, Ross DJ, , eds. Lung and Heart-Lung Transplantation . New York, NY: Taylor & Francis Group; 2006: 147-165
    Google Scholar
  • 84 Whitson BA, Nath DS, Johnson AC , et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131 (1) 73-80
    CrossrefPubMedGoogle Scholar
  • 85 Thabut G, Vinatier I, Stern JB , et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002; 121 (6) 1876-1882
    CrossrefPubMedGoogle Scholar
  • 86 Christie JD, Kotloff RM, Pochettino A , et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124 (4) 1232-1241
    CrossrefPubMedGoogle Scholar
  • 87 Fang A, Studer S, Kawut SM , et al; Lung Transplant Outcomes Group. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139 (4) 782-787
    CrossrefPubMedGoogle Scholar
  • 88 Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18 (4) 755-785
    CrossrefPubMedGoogle Scholar
  • 89 Lynch III JP, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 53-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 83-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Costabel U, Hunninghake GW. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999; 14 (4) 735-737
    CrossrefPubMedGoogle Scholar
  • 92 Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest 2004; 125 (3) 990-996
    CrossrefPubMedGoogle Scholar
  • 93 Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110 (6) 774-802
    PubMedGoogle Scholar
  • 94 Rizzato G, Pezzano A, Sala G , et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64 (2) 121-128
    PubMedGoogle Scholar
  • 95 Głuskowski J, Hawryłkiewicz I, Zych D, Wojtczak A, Zieliński J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46 (1) 26-32
    CrossrefPubMedGoogle Scholar
  • 96 Battesti JP, Georges R, Basset F, Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978; 33 (1) 76-84
    CrossrefPubMedGoogle Scholar
  • 97 Handa T, Nagai S, Miki S , et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129 (5) 1246-1252
    CrossrefPubMedGoogle Scholar
  • 98 Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128 (3) 1483-1489
    CrossrefPubMedGoogle Scholar
  • 99 Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. J Heart Lung Transplant 2008; 27 (3) 329-334
    CrossrefPubMedGoogle Scholar
  • 100 Arcasoy SM, Christie JD, Pochettino A , et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120 (3) 873-880
    CrossrefPubMedGoogle Scholar
  • 101 Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124 (3) 922-928
    CrossrefPubMedGoogle Scholar
  • 102 Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3 (4) 403-407
    PubMedGoogle Scholar
  • 103 Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25 (5) 783-788
    CrossrefPubMedGoogle Scholar
  • 104 Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 (Suppl. 02) S8
    CrossrefPubMedGoogle Scholar
  • 105 Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120 (3) 866-872
    CrossrefPubMedGoogle Scholar
  • 106 Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101 (4) 170-174
    PubMedGoogle Scholar
  • 107 Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23 (11) 1216-1223
    CrossrefPubMedGoogle Scholar
  • 108 Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109 (1) 62-66
    CrossrefPubMedGoogle Scholar
  • 109 Deng JC, Baughman RP, Lynch III JP. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med 2002; 23 (6) 513-527
    Article in Thieme ConnectPubMedGoogle Scholar
  • 110 Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39 (6) 1520-1533
    CrossrefPubMedGoogle Scholar
  • 111 Emirgil C, Sobol BJ, Herbert WH, Trout K. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest 1971; 60 (4) 371-378
    CrossrefPubMedGoogle Scholar
  • 112 Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (1) 207-213
    CrossrefPubMedGoogle Scholar
  • 113 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (2) 296-302
    CrossrefPubMedGoogle Scholar
  • 114 Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138 (5) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 115 Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130 (5) 1481-1488
    CrossrefPubMedGoogle Scholar
  • 116 Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir . Rev 2009; 18 (111) 29-34
    PubMedGoogle Scholar
  • 117 Baughman RP, Judson MA, Lower EE , et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (2) 110-120
    PubMedGoogle Scholar
  • 118 Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (2) 108-116
    PubMedGoogle Scholar
  • 119 Barnett CF, Bonura EJ, Nathan SD , et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135 (6) 1455-1461
    CrossrefPubMedGoogle Scholar
  • 120 Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2008; 75 (2) 211-214
    CrossrefPubMedGoogle Scholar
  • 121 Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 2005; 32 (3) 405-410
    PubMedGoogle Scholar
  • 122 Judson MA, Highland KB, Kwon S , et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (2) 139-145
    PubMedGoogle Scholar
  • 123 Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000; 342 (26) 1969-1978
    CrossrefPubMedGoogle Scholar
  • 124 Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002; 346 (7) 484-490
    CrossrefPubMedGoogle Scholar
  • 125 Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006; 27 (6) 1272-1285
    CrossrefPubMedGoogle Scholar
  • 126 Basset F, Corrin B, Spencer H , et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118 (5) 811-820
    PubMedGoogle Scholar
  • 127 Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 1981; 60 (6) 385-396
    CrossrefPubMedGoogle Scholar
  • 128 Chaowalit N, Pellikka PA, Decker PA , et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79 (10) 1269-1275
    CrossrefPubMedGoogle Scholar
  • 129 Dauriat G, Mal H, Thabut G , et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81 (5) 746-750
    CrossrefPubMedGoogle Scholar
  • 130 Etienne B, Bertocchi M, Gamondes JP , et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med 1998; 157 (1) 288-291
    CrossrefPubMedGoogle Scholar
  • 131 Gabbay E, Dark JH, Ashcroft T , et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53 (4) 326-327
    CrossrefPubMedGoogle Scholar
  • 132 Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest 1997; 111 (4) 1142-1144
    CrossrefPubMedGoogle Scholar
  • 133 Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King Jr TE. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996; 153 (1) 426-435
    CrossrefPubMedGoogle Scholar
  • 134 Hamada K, Teramoto S, Narita N, Yamada E, Teramoto K, Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15 (2) 421-423
    CrossrefPubMedGoogle Scholar
  • 135 Kiakouama L, Cottin V, Etienne-Mastroïanni B, Khouatra C, Humbert M, Cordier JF. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J 2010; 36 (1) 202-204
    CrossrefPubMedGoogle Scholar
  • 136 Benyounes B, Crestani B, Couvelard A, Vissuzaine C, Aubier M. Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X). Chest 1996; 110 (1) 284-286
    CrossrefPubMedGoogle Scholar
  • 137 Ryu JH, Moss J, Beck GJ , et al; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173 (1) 105-111
    CrossrefPubMedGoogle Scholar
  • 138 Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006; 27 (5) 1056-1065
    PubMedGoogle Scholar
  • 139 Johnson SR, Cordier JF, Lazor R , et al; Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35 (1) 14-26
    CrossrefPubMedGoogle Scholar
  • 140 Harknett EC, Chang WY, Byrnes S , et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011; 104 (11) 971-979
    CrossrefPubMedGoogle Scholar
  • 141 Schiavina M, Di Scioscio V, Contini P , et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med 2007; 176 (1) 96-98
    CrossrefPubMedGoogle Scholar
  • 142 Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, Zonnenberg BA, Prokop M. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol 2011; 66 (7) 625-628
    CrossrefPubMedGoogle Scholar
  • 143 Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J, Thiele EA. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet 2009; 46 (7) 465-468
    CrossrefPubMedGoogle Scholar
  • 144 Matsui K, Tatsuguchi A, Valencia J , et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000; 31 (10) 1242-1248
    CrossrefPubMedGoogle Scholar
  • 145 Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000; 216 (1) 147-153
    CrossrefPubMedGoogle Scholar
  • 146 Bernstein SM, Newell Jr JD, Adamczyk D, Mortenson RL, King Jr TE, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?. Am J Respir Crit Care Med 1995; 152 (6, Pt 1) 2138-2143
    CrossrefPubMedGoogle Scholar
  • 147 Taveira-Dasilva AM, Rabel A, Gochuico BR, Avila NA, Moss J. Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril 2011; 96 (3) 711-714 , e1
    CrossrefPubMedGoogle Scholar
  • 148 Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G , et al. Involvement of lymphatics in lymphangioleiomyomatosis. Lymphat Res Biol 2009; 7 (4) 221-228
    CrossrefPubMedGoogle Scholar
  • 149 Taveira-DaSilva AM, Moss J. Optimizing treatments for lymphangioleiomyomatosis. Expert Rev Respir Med 2012; 6 (3) 267-276
    CrossrefPubMedGoogle Scholar
  • 150 Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151 (2, Pt 1) 527-533
    CrossrefPubMedGoogle Scholar
  • 151 Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323 (18) 1254-1260
    CrossrefPubMedGoogle Scholar
  • 152 Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160 (2) 628-633
    CrossrefPubMedGoogle Scholar
  • 153 Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126 (6) 1867-1874
    CrossrefPubMedGoogle Scholar
  • 154 Bissler JJ, McCormack FX, Young LR , et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358 (2) 140-151
    CrossrefPubMedGoogle Scholar
  • 155 McCormack FX, Inoue Y, Moss J , et al; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364 (17) 1595-1606
    CrossrefPubMedGoogle Scholar
  • 156 Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154 (12) 797-805 , W-292–W-293
    CrossrefPubMedGoogle Scholar
  • 157 Moua T, Olson EJ, Jean HC, Ryu JH. Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186 (4) 389-390
    CrossrefPubMedGoogle Scholar
  • 158 Neurohr C, Hoffmann AL, Huppmann P , et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?. Respir Res 2011; 12: 66
    CrossrefPubMedGoogle Scholar
  • 159 Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996; 335 (17) 1275-1280
    CrossrefPubMedGoogle Scholar
  • 160 Pechet TT, Meyers BF, Guthrie TJ , et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2004; 23 (3) 301-308
    CrossrefPubMedGoogle Scholar
  • 161 Maurer JR, Ryu J, Beck G , et al; National Heart, Lung, and Blood Institute LAM Registry Study Group. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry. J Heart Lung Transplant 2007; 26 (12) 1293-1299
    CrossrefPubMedGoogle Scholar
  • 162 Kpodonu J, Massad MG, Chaer RA , et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 2005; 24 (9) 1247-1253
    CrossrefPubMedGoogle Scholar
  • 163 Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007; 132 (5) 1573-1578
    CrossrefPubMedGoogle Scholar
  • 164 Reynaud-Gaubert M, Mornex JF, Mal H , et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation 2008; 86 (4) 515-520
    PubMedGoogle Scholar
  • 165 Harari S, Simonneau G, De Juli E , et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16 (4) 460-463
    PubMedGoogle Scholar
  • 166 Simonneau G, Robbins IM, Beghetti M , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S43-S54
    CrossrefPubMedGoogle Scholar
  • 167 Walter RE, Wilk JB, Larson MG , et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133 (1) 19-25
    CrossrefPubMedGoogle Scholar
  • 168 Cuttica MJ, Kalhan R, Shlobin OA , et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104 (12) 1877-1882
    CrossrefPubMedGoogle Scholar
  • 169 Thabut G, Dauriat G, Stern JB , et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127 (5) 1531-1536
    CrossrefPubMedGoogle Scholar
  • 170 Andersen KH, Iversen M, Kjaergaard J , et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31 (4) 373-380
    CrossrefPubMedGoogle Scholar
  • 171 Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. National Emphysema Treatment Trial (NETT) Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166 (3) 314-322
    CrossrefPubMedGoogle Scholar
  • 172 Stevens D, Sharma K, Szidon P, Rich S, McLaughlin V, Kesten S. Severe pulmonary hypertension associated with COPD. Ann Transplant 2000; 5 (3) 8-12
    PubMedGoogle Scholar
  • 173 Hugues T, Lemoigne F, Macone F, Cerboni P, Gibelin P. [Disproportionate pulmonary arterial hypertension and lung respiratory diseases: distinctive clinical, hemodynamic and prognosis of patients versus primary pulmonary arterial hypertension]. Ann Cardiol Angeiol (Paris) 2012; 61 (1) 1-7
    CrossrefPubMedGoogle Scholar
  • 174 Murray TR, Chen L, Marshall BE, Macarak EJ. Hypoxic contraction of cultured pulmonary vascular smooth muscle cells. Am J Respir Cell Mol Biol 1990; 3 (5) 457-465
    CrossrefPubMedGoogle Scholar
  • 175 Peinado VI, Santos S, Ramírez J, Roca J, Rodriguez-Roisin R, Barberà JA. Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: an in vitro study. Eur Respir J 2002; 20 (2) 332-338
    CrossrefPubMedGoogle Scholar
  • 176 Hales CA. The site and mechanism of oxygen sensing for the pulmonary vessels. Chest 1985; 88 (4, Suppl): 235S-240S
    CrossrefPubMedGoogle Scholar
  • 177 Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study. Lab Invest 1978; 38 (2) 188-200
    PubMedGoogle Scholar
  • 178 Barberà JA, Riverola A, Roca J , et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149 (2, Pt 1) 423-429
    CrossrefPubMedGoogle Scholar
  • 179 Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992; 170 (2) 109-124
    PubMedGoogle Scholar
  • 180 Matsuoka S, Washko GR, Yamashiro T , et al; National Emphysema Treatment Trial Research Group. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 2010; 181 (3) 218-225
    CrossrefPubMedGoogle Scholar
  • 181 Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138 (2) 350-354
    CrossrefPubMedGoogle Scholar
  • 182 Schrijen FV, Henriquez A, Carton D, Delorme N, Butler J. Pulmonary vascular resistance rises with lung volume on exercise in obstructed airflow disease. Clin Physiol 1989; 9 (2) 143-150
    CrossrefPubMedGoogle Scholar
  • 183 Santos S, Peinado VI, Ramírez J , et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19 (4) 632-638
    CrossrefPubMedGoogle Scholar
  • 184 Su Y, Han W, Giraldo C, De Li Y, Block ER. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998; 19 (5) 819-825
    CrossrefPubMedGoogle Scholar
  • 185 Yamato H, Sun JP, Churg A, Wright JL. Guinea pig pulmonary hypertension caused by cigarette smoke cannot be explained by capillary bed destruction. J Appl Physiol 1997; 82 (5) 1644-1653
    PubMedGoogle Scholar
  • 186 Schiess R, Senn O, Fischler M , et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010; 138 (5) 1086-1092
    CrossrefPubMedGoogle Scholar
  • 187 Seimetz M, Parajuli N, Pichl A , et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147 (2) 293-305
    CrossrefPubMedGoogle Scholar
  • 188 Peinado VI, Barberá JA, Abate P , et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (5, Pt 1) 1605-1611
    CrossrefPubMedGoogle Scholar
  • 189 Chaouat A, Savale L, Chouaid C , et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136 (3) 678-687
    CrossrefPubMedGoogle Scholar
  • 190 Churg A, Marshall CV, Sin DD , et al. Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185 (1) 34-43
    CrossrefPubMedGoogle Scholar
  • 191 Wick MJ, Buesing EJ, Wehling CA , et al. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183 (3) 330-340
    CrossrefPubMedGoogle Scholar
  • 192 Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: The vascular story. Pulm Circ 2011; 1 (3) 320-326
    CrossrefPubMedGoogle Scholar
  • 193 Peinado VI, Barbera JA, Ramirez J , et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274 (6, Pt 1) L908-L913
    PubMedGoogle Scholar
  • 194 Dinh-Xuan AT, Higenbottam TW, Clelland CA , et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324 (22) 1539-1547
    CrossrefPubMedGoogle Scholar
  • 195 Noureddine H, Gary-Bobo G, Alifano M , et al. Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circ Res 2011; 109 (5) 543-553
    CrossrefPubMedGoogle Scholar
  • 196 Oswald-Mammosser M, Apprill M, Bachez P, Ehrhart M, Weitzenblum E. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration 1991; 58 (5-6) 304-310
    CrossrefPubMedGoogle Scholar
  • 197 Kiakouama L, Cottin V, Glerant JC, Bayle JY, Mornex JF, Cordier JF. Conditions associated with severe carbon monoxide diffusion coefficient reduction. Respir Med 2011; 105 (8) 1248-1256
    CrossrefPubMedGoogle Scholar
  • 198 Rizzato GF, Rampulla C, Mandelli V, Benza GC, Mantero O, Morpurgo M. Can pulmonary artery pressure be predicted without right heart catheterization in chronic obstructive lung disease?. Acta Cardiol 1975; 30 (4) 251-265
    PubMedGoogle Scholar
  • 199 Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009; 136 (2) 412-419
    CrossrefPubMedGoogle Scholar
  • 200 Bishop JM, Cross KW. Use of other physiological variables to predict pulmonary arterial pressure in patients with chronic respiratory disease. Multicentre study. Eur Heart J 1981; 2 (6) 509-517
    PubMedGoogle Scholar
  • 201 Ooi H, Cadogan E, Sweeney M, Howell K, O'Regan RG, McLoughlin P. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 2000; 278 (2) H331-H338
    PubMedGoogle Scholar
  • 202 Hurdman J, Condliffe R, Elliot CA , et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39 (4) 945-955
    CrossrefPubMedGoogle Scholar
  • 203 Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286 (17) 912-918
    CrossrefPubMedGoogle Scholar
  • 204 Oswald-Mammosser M, Weitzenblum E, Quoix E , et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107 (5) 1193-1198
    CrossrefPubMedGoogle Scholar
  • 205 Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36 (10) 752-758
    CrossrefPubMedGoogle Scholar
  • 206 Skwarski K, MacNee W, Wraith PK, Sliwinski P, Zielinski J. Predictors of survival in patients with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Chest 1991; 100 (6) 1522-1527
    CrossrefPubMedGoogle Scholar
  • 207 Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1 (8222) 681-686
    PubMedGoogle Scholar
  • 208 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93 (3) 391-398
    CrossrefPubMedGoogle Scholar
  • 209 Keller R, Ragaz A, Borer P. Predictors for early mortality in patients with long-term oxygen home therapy. Respiration 1985; 48 (3) 216-221
    CrossrefPubMedGoogle Scholar
  • 210 Finlay M, Middleton HC, Peake MD, Howard P. Cardiac output, pulmonary hypertension, hypoxaemia and survival in patients with chronic obstructive airways disease. Eur J Respir Dis 1983; 64 (4) 252-263
    PubMedGoogle Scholar
  • 211 Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 2011; 189 (3) 207-212
    CrossrefPubMedGoogle Scholar
  • 212 Orens JB, Estenne M, Arcasoy S , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (7) 745-755
    CrossrefPubMedGoogle Scholar
  • 213 Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (1) 158-164
    CrossrefPubMedGoogle Scholar
  • 214 McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132 (6) 1748-1755
    CrossrefPubMedGoogle Scholar
  • 215 Wells JM, Washko GR, Han MK , et al; COPDGene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367 (10) 913-921
    CrossrefPubMedGoogle Scholar
  • 216 Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke SW, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studies by serial observations during recovery. Circ Res 1969; 24 (1) 51-60
    CrossrefPubMedGoogle Scholar
  • 217 Akcay M, Yeter E, Durmaz T , et al. Treatment of acute chronic obstructive pulmonary disease exacerbation improves right ventricle function. Eur J Echocardiogr 2010; 11 (6) 530-536
    CrossrefPubMedGoogle Scholar
  • 218 Weitzenblum E, Schrijen F, Mohan-Kumar T, Colas des Francs V, Lockhart A. Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis. Chest 1988; 94 (4) 772-778
    CrossrefPubMedGoogle Scholar
  • 219 Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest 1984; 85 (1) 6-14
    CrossrefPubMedGoogle Scholar
  • 220 Raeside DA, Brown A, Patel KR, Welsh D, Peacock AJ. Ambulatory pulmonary artery pressure monitoring during sleep and exercise in normal individuals and patients with COPD. Thorax 2002; 57 (12) 1050-1053
    CrossrefPubMedGoogle Scholar
  • 221 Catterall JR, Douglas NJ, Calverley PM , et al. Transient hypoxemia during sleep in chronic obstructive pulmonary disease is not a sleep apnea syndrome. Am Rev Respir Dis 1983; 128 (1) 24-29
    PubMedGoogle Scholar
  • 222 Sabit R, Bolton CE, Fraser AG , et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med 2010; 104 (8) 1171-1178
    CrossrefPubMedGoogle Scholar
  • 223 Oliver RM, Fleming JS, Waller DG. Right ventricular function at rest and during exercise in chronic obstructive pulmonary disease. Comparison of two radionuclide techniques. Chest 1993; 103 (1) 74-80
    CrossrefPubMedGoogle Scholar
  • 224 Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med 2010; 104 (1) 121-126
    CrossrefPubMedGoogle Scholar
  • 225 Boerrigter BG, Bogaard HJ, Trip P , et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142 (5) 1166-1174
    CrossrefPubMedGoogle Scholar
  • 226 Fisher MR, Criner GJ, Fishman AP , et al; NETT Research Group. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30 (5) 914-921
    CrossrefPubMedGoogle Scholar
  • 227 Oswald-Mammosser M, Oswald T, Nyankiye E, Dickele MC, Grange D, Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis 1987; 71 (5) 419-429
    PubMedGoogle Scholar
  • 228 Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. Eur Heart J 1991; 12 (2) 103-111
    PubMedGoogle Scholar
  • 229 Chi SY, Kim EY, Ban HJ , et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 2012; 190 (3) 271-276
    CrossrefPubMedGoogle Scholar
  • 230 Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130 (6) 993-998
    PubMedGoogle Scholar
  • 231 Kessler R, Faller M, Weitzenblum E , et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164 (2) 219-224
    CrossrefPubMedGoogle Scholar
  • 232 Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009; 135 (3) 786-793
    CrossrefPubMedGoogle Scholar
  • 233 Rao BS, Cohn KE, Eldridge FE, Hancock EW. Left ventricular failure secondary to chronic pulmonary disease. Aspen Emphysema Conf 1968; 11: 129-134
    PubMedGoogle Scholar
  • 234 Barr RG, Bluemke DA, Ahmed FS , et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362 (3) 217-227
    CrossrefPubMedGoogle Scholar
  • 235 Watz H, Waschki B, Meyer T , et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010; 138 (1) 32-38
    CrossrefPubMedGoogle Scholar
  • 236 Anderson WJ, Lipworth BJ. Relationships between impulse oscillometry, spirometry and dyspnoea in COPD. J R Coll Physicians Edinb 2012; 42 (2) 111-115
    PubMedGoogle Scholar
  • 237 Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84 (5) 365-369
    CrossrefPubMedGoogle Scholar
  • 238 Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration 1993; 60 (6) 354-358
    CrossrefPubMedGoogle Scholar
  • 239 Doherty MJ, Pearson MG, O'Grady EA, Pellegrini V, Calverley PM. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52 (11) 998-1002
    CrossrefPubMedGoogle Scholar
  • 240 Aduen JF, Zisman DA, Mobin SI , et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc 2007; 82 (1) 48-54
    PubMedGoogle Scholar
  • 241 Mejía M, Carrillo G, Rojas-Serrano J , et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136 (1) 10-15
    CrossrefPubMedGoogle Scholar
  • 242 Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010; 188 (5) 365-373
    CrossrefPubMedGoogle Scholar
  • 243 Akagi T, Matsumoto T, Harada T , et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009; 103 (8) 1209-1215
    CrossrefPubMedGoogle Scholar
  • 244 Kurashima K, Takayanagi N, Tsuchiya N , et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 2010; 15 (5) 843-848
    CrossrefPubMedGoogle Scholar
  • 245 Todd NW, Jeudy J, Lavania S , et al. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Fibrogenesis Tissue Repair 2011; 4 (1) 6
    CrossrefPubMedGoogle Scholar
  • 246 Cottin V, Nunes H, Brillet PY , et al; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26 (4) 586-593
    CrossrefPubMedGoogle Scholar
  • 247 Cottin V, Le Pavec J, Prévot G , et al; GERM”O”P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35 (1) 105-111
    CrossrefPubMedGoogle Scholar
  • 248 Morrell NW, Sarybaev AS, Alikhan A, Mirrakhimov MM, Aldashev AA. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders. Lancet 1999; 353 (9155) 814
    CrossrefPubMedGoogle Scholar
  • 249 van Suylen RJ, Wouters EF, Pennings HJ , et al. The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (6) 1791-1795
    CrossrefPubMedGoogle Scholar
  • 250 Eddahibi S, Chaouat A, Morrell N , et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108 (15) 1839-1844
    CrossrefPubMedGoogle Scholar
  • 251 Shaw JG, Dent AG, Passmore LH , et al. Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulm Med 2012; 12: 25
    CrossrefPubMedGoogle Scholar
  • 252 Castaldi PJ, Cho MH, Cohn M , et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet 2010; 19 (3) 526-534
    CrossrefPubMedGoogle Scholar
  • 253 Eddahibi S, Chaouat A, Tu L , et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (6) 475-476
    CrossrefPubMedGoogle Scholar
  • 254 Yildiz P, Oflaz H, Cine N, Erginel-Unaltuna N, Erzengin F, Yilmaz V. Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD. Respir Med 2003; 97 (12) 1282-1288
    CrossrefPubMedGoogle Scholar
  • 255 Kanazawa H, Tateishi Y, Yoshikawa J. Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms. Clin Physiol Funct Imaging 2004; 24 (4) 224-228
    CrossrefPubMedGoogle Scholar
  • 256 Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax 2003; 58 (7) 629-631
    CrossrefPubMedGoogle Scholar
  • 257 Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162 (4, Pt 1) 1235-1238
    CrossrefPubMedGoogle Scholar
  • 258 de Torres JP, Cote CG, López MV , et al. Sex differences in mortality in patients with COPD. Eur Respir J 2009; 33 (3) 528-535
    CrossrefPubMedGoogle Scholar
  • 259 Ekström MP, Jogréus C, Ström KE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS ONE 2012; 7 (4) e35806
    CrossrefPubMedGoogle Scholar
  • 260 Shimizu M, Imanishi J, Takano T, Miwa Y. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension. Intern Med 2011; 50 (20) 2341-2346
    CrossrefPubMedGoogle Scholar
  • 261 Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79 (5) 377-382
    CrossrefPubMedGoogle Scholar
  • 262 Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347 (8999) 436-440
    CrossrefPubMedGoogle Scholar
  • 263 Vonbank K, Ziesche R, Higenbottam TW , et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003; 58 (4) 289-293
    CrossrefPubMedGoogle Scholar
  • 264 Blanco I, Gimeno E, Munoz PA , et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181 (3) 270-278
    CrossrefPubMedGoogle Scholar
  • 265 Holverda S, Rietema H, Bogaard HJ , et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 2008; 21 (3) 558-564
    CrossrefPubMedGoogle Scholar
  • 266 Lederer DJ, Bartels MN, Schluger NW , et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9 (3) 268-275
    CrossrefPubMedGoogle Scholar
  • 267 Namendys-Silva SA, Hernández-Garay M. Should we administer sildenafil to patients with obstructive pulmonary disease and pulmonary hypertension? No. Am J Respir Crit Care Med 2010; 182 (9) 1206 , author reply 1206–1207
    CrossrefPubMedGoogle Scholar
  • 268 Kim HS, Park JH, Park SJ, Park JK, Lee HB. Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. Korean J Intern Med 2007; 22 (1) 37-39
    CrossrefPubMedGoogle Scholar
  • 269 Park JS, Lim HJ, Cho YJ, Lee JH, Yoon HI, Lee CT. Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. COPD 2012; 9 (5) 499-504
    CrossrefPubMedGoogle Scholar
  • 270 Stolz D, Rasch H, Linka A , et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32 (3) 619-628
    CrossrefPubMedGoogle Scholar
  • 271 Mercurio V, Carlomagno G, Fazio S. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. Heart Lung 2012; 41 (5) 512-517
    PubMedGoogle Scholar
  • 272 Reed RM, Iacono A, DeFilippis A , et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD 2011; 8 (2) 96-102
    CrossrefPubMedGoogle Scholar
  • 273 Wright JL, Zhou S, Preobrazhenska O , et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011; 183 (1) 50-58
    CrossrefPubMedGoogle Scholar
  • 274 Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res 2011; 12: 45
    CrossrefPubMedGoogle Scholar
  • 275 Zakynthinos E, Daniil Z, Papanikolaou J, Makris D. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets 2011; 12 (4) 501-513
    CrossrefPubMedGoogle Scholar
  • 276 Barberà JA, Peinado VI. Vascular progenitor cells in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011; 8 (6) 528-534
    CrossrefPubMedGoogle Scholar
  • 277 Dumas de La Roque E, Savineau JP, Metivier AC , et al. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Ann Endocrinol (Paris) 2012; 73 (1) 20-25
    CrossrefPubMedGoogle Scholar